JP2018522945A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018522945A5 JP2018522945A5 JP2018522878A JP2018522878A JP2018522945A5 JP 2018522945 A5 JP2018522945 A5 JP 2018522945A5 JP 2018522878 A JP2018522878 A JP 2018522878A JP 2018522878 A JP2018522878 A JP 2018522878A JP 2018522945 A5 JP2018522945 A5 JP 2018522945A5
- Authority
- JP
- Japan
- Prior art keywords
- bilastin
- crystal form
- temperature
- preparing
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000013078 crystal Substances 0.000 claims 27
- 238000000034 method Methods 0.000 claims 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 12
- 238000001816 cooling Methods 0.000 claims 5
- 238000002425 crystallisation Methods 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 238000002360 preparation method Methods 0.000 claims 5
- 230000007704 transition Effects 0.000 claims 5
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims 4
- 230000008025 crystallization Effects 0.000 claims 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims 3
- 239000006185 dispersion Substances 0.000 claims 3
- 238000001035 drying Methods 0.000 claims 3
- 238000003756 stirring Methods 0.000 claims 3
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- 238000002441 X-ray diffraction Methods 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 229960001340 histamine Drugs 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 238000010899 nucleation Methods 0.000 claims 2
- 238000002636 symptomatic treatment Methods 0.000 claims 2
- 238000002411 thermogravimetry Methods 0.000 claims 2
- 230000004580 weight loss Effects 0.000 claims 2
- 208000024780 Urticaria Diseases 0.000 claims 1
- 208000030961 allergic reaction Diseases 0.000 claims 1
- 239000011260 aqueous acid Substances 0.000 claims 1
- ACCMWZWAEFYUGZ-UHFFFAOYSA-N bilastine Chemical compound N=1C2=CC=CC=C2N(CCOCC)C=1C(CC1)CCN1CCC1=CC=C(C(C)(C)C(O)=O)C=C1 ACCMWZWAEFYUGZ-UHFFFAOYSA-N 0.000 claims 1
- 229960004314 bilastine Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000001932 seasonal effect Effects 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES201531103 | 2015-07-24 | ||
| ESP201531103 | 2015-07-24 | ||
| PCT/ES2016/070560 WO2017017301A1 (es) | 2015-07-24 | 2016-07-22 | Formas cristalinas de bilastina y procedimientos para su preparación |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018522945A JP2018522945A (ja) | 2018-08-16 |
| JP2018522945A5 true JP2018522945A5 (enExample) | 2019-08-22 |
| JP7168447B2 JP7168447B2 (ja) | 2022-11-09 |
Family
ID=57884122
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018522878A Active JP7168447B2 (ja) | 2015-07-24 | 2016-07-22 | ビラスチンの結晶形態及びそれらの調製方法 |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP3327012B1 (enExample) |
| JP (1) | JP7168447B2 (enExample) |
| KR (1) | KR102657147B1 (enExample) |
| CN (1) | CN107849007B (enExample) |
| CA (1) | CA2993134A1 (enExample) |
| CY (1) | CY1124505T1 (enExample) |
| ES (2) | ES2600827B9 (enExample) |
| LT (1) | LT3327012T (enExample) |
| MX (1) | MX382563B (enExample) |
| PL (1) | PL3327012T3 (enExample) |
| PT (1) | PT3327012T (enExample) |
| SI (1) | SI3327012T1 (enExample) |
| WO (1) | WO2017017301A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3452462A4 (en) * | 2016-05-05 | 2019-10-23 | MSN Laboratories Private Limited, R&D Center | Solid state forms of 2-[4-(2-{4-[1-(2-ethoxyethyl)-1h-benzimidazol-2-yl]-1-piperidinyl}ethyl)phenyl]-2-methylpropanoic acid and process for preparation thereof |
| EP3453384B1 (en) | 2017-09-07 | 2020-05-27 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Pharmaceutical tablet composition comprising bilastine |
| ES2835287T3 (es) | 2017-12-18 | 2021-06-22 | Tiefenbacher Alfred E Gmbh & Co Kg | Composición farmacéutica de comprimido que comprende la forma polimórfica 3 de bilastina y aluminometasilicato de magnesio |
| EP3641735B1 (en) | 2017-12-18 | 2021-02-24 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Pharmaceutical tablet composition comprising bilastine form 3 and a water-soluble filler |
| BR112021005403A2 (pt) * | 2018-09-25 | 2021-06-15 | Glenmark Life Sciences Limited | processos para a preparação de forma cristalina 2 de bilastina e para a preparação de solvato de p-xileno de bilastina, e, solvato de p-xileno de bilastina |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2124167B1 (es) * | 1996-06-04 | 1999-09-16 | Espanola Prod Quimicos | Nuevos derivados del bencimidazol con actividad antihistaminica. |
| BRPI0215703B8 (pt) * | 2002-04-19 | 2021-05-25 | Faes Farma Sa | polimorfo de ácido 4-[2-[1-(2-etoxietil)-1h-benzidimazol-2-il]-1-piperidinil]etil]-a, a-dimetil-benzenoacético, preparado farmacêutico, e seu uso do polimorfo 1 |
| CZ307500B6 (cs) * | 2012-08-15 | 2018-10-24 | Zentiva, K.S. | Způsob přípravy derivátu 2-methyl-2´-fenylpropionové kyseliny využívající nové intermediáty |
| CN103214454A (zh) * | 2013-03-30 | 2013-07-24 | 北京万全德众医药生物技术有限公司 | 一种比拉斯汀晶型及制备方法 |
| CN104447682A (zh) * | 2013-09-12 | 2015-03-25 | 天津市汉康医药生物技术有限公司 | 比拉斯汀化合物 |
| CN104447683A (zh) * | 2013-09-12 | 2015-03-25 | 天津市汉康医药生物技术有限公司 | 一种稳定的比拉斯汀化合物 |
| SK7066Y1 (sk) * | 2014-01-29 | 2015-03-03 | Zentiva Ks | Kryštalický dihydrát bilastínu |
| CN103788062A (zh) * | 2014-02-17 | 2014-05-14 | 北京博泽德润医药科技开发有限公司 | 一种比拉斯汀晶型及其制备方法 |
| CN104151290A (zh) * | 2014-06-30 | 2014-11-19 | 北京万全德众医药生物技术有限公司 | 一种制备比拉斯汀新晶型的方法 |
| CN104177331B (zh) * | 2014-09-10 | 2016-08-17 | 北京科莱博医药开发有限责任公司 | 比拉斯汀的制备方法 |
| CN104530002B (zh) * | 2015-01-29 | 2017-06-09 | 天津梅花生物医药科技有限公司 | 比拉斯汀化合物及其制备方法 |
-
2016
- 2016-07-22 EP EP16829901.4A patent/EP3327012B1/en active Active
- 2016-07-22 WO PCT/ES2016/070560 patent/WO2017017301A1/es not_active Ceased
- 2016-07-22 ES ES201690068A patent/ES2600827B9/es not_active Expired - Fee Related
- 2016-07-22 ES ES16829901T patent/ES2874577T3/es active Active
- 2016-07-22 KR KR1020187003411A patent/KR102657147B1/ko active Active
- 2016-07-22 JP JP2018522878A patent/JP7168447B2/ja active Active
- 2016-07-22 MX MX2018000883A patent/MX382563B/es unknown
- 2016-07-22 CN CN201680042950.8A patent/CN107849007B/zh active Active
- 2016-07-22 SI SI201631236T patent/SI3327012T1/sl unknown
- 2016-07-22 LT LTEP16829901.4T patent/LT3327012T/lt unknown
- 2016-07-22 PL PL16829901T patent/PL3327012T3/pl unknown
- 2016-07-22 CA CA2993134A patent/CA2993134A1/en active Pending
- 2016-07-22 PT PT168299014T patent/PT3327012T/pt unknown
-
2021
- 2021-06-16 CY CY20211100536T patent/CY1124505T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6689942B2 (ja) | オメカムチブメカルビルの塩及び塩を調製するプロセス | |
| JP2018522945A5 (enExample) | ||
| CA2743426C (en) | New crystal form of sunitinib malate | |
| JP2005503386A5 (enExample) | ||
| JP6779972B2 (ja) | 呼吸器合胞体ウイルス（ｒｓｖ）感染症の処置のためのｎ−［（３−アミノ−３−オキセタニル）メチル］−２−（２，３−ジヒドロ−１，１−ジオキシド−１，４−ベンゾチアゼピン−４（５ｈ）−イル）−６−メチル−４−キナゾリンアミンの結晶形 | |
| JP2019504103A5 (enExample) | ||
| JP2018501289A (ja) | ネラチニブマレイン酸塩の新規な結晶形及びその製造方法 | |
| JP6937322B2 (ja) | 置換ピペリジン化合物の塩 | |
| CN105324375A (zh) | 盐酸尼洛替尼的多晶型形式 | |
| JP2012500819A5 (enExample) | ||
| JP2010532357A (ja) | １，２−置換３，４−ジオキソ−１−シクロブテン化合物における制御された結晶サイズのための方法 | |
| JP2022535870A (ja) | Ｃｄｋ９阻害剤の結晶多形体及びその製造方法と用途 | |
| CN115819257A (zh) | 维兰特罗三苯乙酸盐的新结晶形式及其制备方法 | |
| JP2018522945A (ja) | ビラスチンの結晶形態及びそれらの調製方法 | |
| HUP0301116A2 (hu) | (R)-n-[5-metil-8-(4-metil-1-piperazinil)-1,2,3,4-tetrahidro-2-naftil]-4-morfolino-benzamid új formája, eljárás az ellőállítására és ezt tartalmazó gyógyszerkészítmény | |
| JP2018030884A (ja) | テノホビルの固体形態 | |
| CN114787149A (zh) | (s)-1-(1-丙烯酰吡咯烷-3-基)-3-((3，5-二甲氧苯基)乙炔基)-5-(甲基氨基)-1h-吡唑-4-甲酰胺的晶型 | |
| JP2010502682A5 (enExample) | ||
| CN103864752B (zh) | 甲磺酸伊马替尼的晶型及其制备方法 | |
| JP2020517674A (ja) | ボルチオキセチンＨＢｒ α型を製造するための方法 | |
| JP2024530315A (ja) | Ｂｃｌ－２阻害剤の固体形態、それらの調製方法及び使用方法 | |
| CN115403560B (zh) | 一种艾普拉唑镁晶型及其制备方法 | |
| CN103694171B (zh) | 盐酸屈他维林晶型iii和晶型iv及其制备方法 | |
| CN102633775B (zh) | 一种甲磺酸伊马替尼α晶型的制备方法 | |
| JPWO2020228746A5 (enExample) |